Both drive p21 downregulation affecting its tumor suppressive activity and being linked to poor prognosis of patients with colorectal cancer, non-small-cell lung carcinoma, breast, gastric and ovarian cancers [2] as well as pancreatic cancer [156]. Here, CDKN1A is linked to familial pancreatic carcinoma.